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Abstract
Background: To compare the survival outcomes and acute toxicities of concurrent chemoradiotherapy (CCRT),
induction chemotherapy (IC) plus radiotherapy (RT), and IC plus CCRT in patients with locoregionally advanced
nasopharyngeal carcinoma (NPC) treated using intensity-modulated radiotherapy (IMRT).
Methods: Patients with stage III–IVB NPC who were treated with IMRT between 2009 and 2012 at a single
institution were retrospectively reviewed. The induction regimens included PF (cisplatin and fluorouracil) and TP
(docetaxel and cisplatin) every 3 weeks for 2–3 cycles; the concurrent regimen was cisplatin every three weeks for
2–3 cycles. A propensity score matching method was used to match patients from each group in a 1:1:1 ratio.
Results: In total, 147 eligible patients were propensity-matched, with 49 patients in each treatment group. The
median follow-up duration was 38.5 months (range, 4.5 – 56 months). The 3-year disease-free survival, overall
survival, distant metastasis-free survival, and locoregional relapse-free survival rates were 82.1 %, 92.8 %, 87 %, and
90.4 % in the CCRT group; 86.3 %, 91.0 %, 91.6 %, and 94.4 % in the IC plus RT group; and 87.8 %, 95.8 %, 93.8 %,
and 93.9 % in the IC plus CCRT group, respectively. No statistically significant survival differences were observed
between the three treatment groups in either univariate or multivariate analyses. The incidence of grade 3–4 acute
toxicities was similar among groups.
Conclusions: This study suggests that CCRT, IC plus RT, and IC plus CCRT are similarly efficacious treatment
strategies for patients with locoregionally advanced NPC treated using IMRT; however, long-term, large-scale
randomized trials are required to confirm these findings.
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Background
Nasopharyngeal carcinoma (NPC) is the most common
malignant head and neck cancer in Southern China, and
over 70 % of cases of newly-diagnosed NPC are classified
as locoregionally advanced disease [1, 2]. Concurrent
chemoradiotherapy (CCRT) is the standard treatment
for locoregionally advanced NPC. Randomized trials [3–9]
and meta-analyses [10–12] have demonstrated that CCRT
can significantly improve locoregional and distant control
compared to radiotherapy (RT) alone, which has ultim-
ately improved overall survival (OS) in locoregionally
advanced NPC.
Induction chemotherapy (IC) before RT may also reduce
the risk of locoregional recurrence and distant metastasis in
NPC [13]. Compared to concurrent chemotherapy, IC may
offer the benefits of early eradication of micrometastases
and reduction of the tumor burden, and not increase toxic-
ities during RT. Although the results of randomized trials
investigating the value of adding IC to RT [14–17] or
CCRT [18–20] are controversial, a meta-analysis of these
trials indicated that IC could effectively reduce the rate of
distant metastasis and improve OS in locoregionally
advanced NPC [21].
Intensity-modulated radiotherapy (IMRT) has now re-
placed two-dimensional conventional radiotherapy
(2DCRT) as the mainstay RT technique for NPC. Com-
pared to 2DCRT, IMRT leads to significantly better
treatment outcomes by achieving a higher local control
rate. However, distant metastasis has become the major
treatment failure pattern in NPC [22–24]. Although IC
and concurrent chemotherapy may both improve this, a
direct comparison of these two approaches has not been
conducted in patients with NPC treated using IMRT.
Moreover, it remains uncertain whether combining IC
and CCRT can further reduce the risk of distant metas-
tasis. Therefore, we conducted a retrospective study to
compare the survival outcomes and acute toxicities of
CCRT, IC plus RT, and IC plus CCRT in patients treated
with IMRT, in order to help guide treatment strategy se-
lection for patients with locoregionally advanced NPC.
Methods
Patients
Patients with newly diagnosed, non-distant metastatic,
histologically-proven NPC treated with IMRT at our Can-
cer Center between October 2009 and February 2012 were
retrospectively reviewed. The pre-treatment evaluation in-
cluded a complete patient history, physical examination,
hematology and biochemistry profiles, nasopharyngeal
fiberoptic endoscopy, MRI of the nasopharynx and neck,
chest radiography, abdominal sonography and whole body
bone scan using 99mTc-methyldiphosphonate single pho-
ton emission computed tomography (SPECT). Only pa-
tients with stage III-IVB disease according to the 7th edition
of the UICC/AJCC staging system [25] who received the
study-defined IC or CCRT regimens were included in this
study. The patients were classified into three treatment
groups: (1) CCRT group, (2) IC plus RT group, and (3) IC
plus CCRT group. The study was approved by the Institu-
tional Review Board of Sun Yat-sen University Cancer Cen-
ter. All patients provided written informed consent for
participation in the study and analysis of their medical
records.
Radiotherapy
All patients received radical IMRT to treat the nasopha-
ryngeal and neck tumor volumes for the entire treat-
ment course. All patients were immobilized in the
supine position using a head, neck and shoulder thermo-
plastic mask. Intravenous contrast-enhanced CT simula-
tion was performed at 3 mm intervals from the head to
2 cm below the sternoclavicular joint using a CT simula-
tor. Target volumes were delineated slice-by-slice on
treatment planning CT scans according to an individualized
delineation protocol, in accordance with the International
Commission on Radiation Units and Measurements reports
50 and 62. The prescribed doses were 68–72 Gy in 30–33
fractions to the planning target volume (PTV) of the pri-
mary gross tumor volume (GTVnx), 64–70 Gy to the
PTV of the GTV of the involved lymph nodes
(GTVnd), 60–63 Gy to the PTV of the high-risk clin-
ical target volume (CTV1), and 54–56 Gy to the PTV
of the low-risk clinical target volume (CTV2). All tar-
gets were treated simultaneously using the simultan-
eous integrated boost technique.
Chemotherapy
During the study period, the institutional guidelines rec-
ommended CCRT ± induction and/or adjuvant chemo-
therapy for stage III to IVB disease. Reasons for
deviating from the institutional guidelines included
organ dysfunction suggesting intolerance to chemother-
apy, patient refusal, and the discretion of the doctors in
individual cases. The study-defined IC regimens included
PF (80 mg/m2 cisplatin on day 1 and 800 mg/m2/d fluoro-
uracil civ on days 1–5) or TP (75 mg/m2 docetaxel on day
1 and 75 mg/m2 cisplatin on day 1); both regimens were
repeated every 3 weeks for 2–3 cycles. The study-defined
CCRT regimen was 80–100 mg/m2 cisplatin on day 1
every 3 weeks for 2–3 cycles. Patients receiving other
chemotherapy regimens or who received only one cycle of
induction or concurrent chemotherapy were excluded
from this study.
Follow-up and statistical analysis
Patient follow-up was measured from the first day of
therapy to the day of last examination or death. Patients
were examined at least every 3 months during the first
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2 years, with follow-up examinations every 6 months for
3 years or until death. Disease–free survival (DFS) was cal-
culated from day 1 of treatment to locoregional relapse,
distant relapse or tumor-related death, whichever oc-
curred first. OS was calculated from day 1 of treatment to
last examination or death; distant metastasis–free survival
(DMFS) and locoregional relapse–free survival (LRRFS),
to first distant metastasis and locoregional relapse,
respectively.
All statistical analyses were performed using SPSS v
18.0 (Chicago, IL, USA). A propensity score matching
method [26, 27] was used to match the patients from
each of the three groups (CCRT, IC plus RT, and IC plus
CCRT) in a 1:1:1 ratio. Categorical variables were com-
pared using the Chi–square test (or Fisher’s exact test, if
the expected number was less than five in at least 25 %
of the cells), and continuous variables were compared
using ANOVA. Survival rates were calculated using the
Kaplan-Meier method and the log-rank test was used to
perform paired comparisons between each of the treat-
ment groups using the pair-wise over strata method.
Multivariate analyses with the Cox proportional hazards
model [28] were used to calculate hazard ratios (HR),
95 % confidence intervals (CI) and test the independent
significance of different factors by backward elimination
of insignificant variables. Two-tailed P-values < 0.05 were
considered statistically significant; P -value corrections
for multiple comparisons were not performed.
Results
Characteristics of the patients in the propensity-matched
groups
A total of 305 eligible patients were enrolled. CCRT was
delivered to 198 patients, IC plus RT to 49 patients, and
IC plus CCRT to 58 patients. In the 49 patients in the
IC plus RT group, the reasons for not receiving concur-
rent chemotherapy were as follows: bone marrow de-
pression (8/49, 16.3 %), liver dysfunction (3/49, 6.1 %),
patient refusal (21/49, 42.9 %), and doctors’ discretion
(17/49, 34.7 %). The characteristics of the patients were
not balanced in the three treatment groups: the percent-
age of patients with stage IVA-B disease was higher in
the IC plus CCRT group (27/58, 46.6 %) than in the IC
plus RT group (18/49, 36.7 %) and then in the CCRT
group (46/198, 23.2 %, P = 0.002). Clinical variables in-
cluding sex, age, T-category, N-category and overall
stage were used to generate a propensity score model.
Eventually, 147 patients were propensity matched to cre-
ate three groups each containing 49 patients. The char-
acteristics of the patients were well-balanced between
the propensity-matched groups (Table 1).
All patients completed the planned IMRT protocol.
The median RT dose was 68 Gy (range, 68–72) in the
CCRT group, and 70 Gy (range, 68–72) in the other two
groups. All patients received at least two cycles of
chemotherapy; more patients in the IC plus RT group
received three cycles of IC than patients in the IC plus
CCRT group (32.7 % vs. 20.4 %), and more patients in
the CCRT group received three cycles of concurrent cis-
platin than patients in the IC plus CCRT group (18.4 %
vs. 8.2 %). However, the differences were not statistically
significant (Table 2). Of the 98 patients receiving IC, 57
(58.2 %) received the PF regimen and 41 (41.8 %) re-
ceived the TP regimen; patient characteristics were simi-
lar between the PF and TP groups (data not shown).
Survival outcomes
The median follow-up time for the 147 propensity
score-matched patients was 38.5 months (range, 4.5–56
months). A total of 20/147 (13.6 %) patients experienced
treatment failure or death, nine (6.1 %) experienced
locoregional recurrence, 13 (8.8 %) experienced distant
metastasis, and 10 (6.8 %) patients died. For the CCRT
group, the 3-year DFS, OS, DMFS, and LRRFS rates
were 82.1 %, 92.8 %, 87 %, and 90.4 %, respectively. For
the IC plus RT group, the 3-year DFS, OS, DMFS, and
LRRFS rates were 86.3 %, 91 %, 91.6 %, and 94.4 %, re-
spectively. For the IC plus CCRT group, the 3-year DFS,
OS, DMFS, and LRRFS rates were 87.8 %, 95.8 %,
93.8 %, and 93.9 %, respectively. No statistically signifi-
cant survival differences were observed between the
three treatment groups (Table 3, Fig. 1). Of the 98 pa-
tients receiving IC, those who received the TP regimen
had similar 3-year DFS (p = 0.531), OS (p = 0.686),
DMFS (p = 0.465) and LRRFS (p = 0.937) compared with
patients who received the PF regimen.
Multivariate analyses
Multivariate analyses were performed to further adjust for
various prognostic factors. The following parameters were
included in the Cox proportional hazards model: sex
(female vs. male), age (>45 years vs. ≤45 years), T-
category (T4 vs. T1-3), N-category (N2-3 vs. N0-1),
RT dose (>68 Gy vs. 68 Gy) and chemotherapeutic
intervention (IC plus CCRT vs. IC plus RT vs. CCRT).
Multivariate analyses demonstrated that treatment group
was not a significant prognostic factor for any endpoint
(Table 4). N-category was an independent prognostic factor
for DFS (P = 0.005) and DMFS (P = 0.001), and T-category
was an independent prognostic factor for DFS (P = 0.048).
Acute toxicities
No treatment-related deaths were observed in any group.
Acute toxicities were similar between groups (Table 5);
32.7 % (16/49) of patients in the CCRT group, 38.8 % (19/
49) of patients in the IC plus RT group, and 40.8 % (20/49)
of patients in the IC plus CCRT group experienced grade
3–4 acute toxicities (P = 0.685). The most frequent
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Table 2 Summary of treatments for the 147 propensity-matched patients
Treatment CCRT group (n = 49) IC plus RT group (n = 49) IC plus CCRT group (n = 49) P value
RT dose (Gy) 0.004*
Median (range) 68 (68–72) 70 (68–72) 70 (68–72)
RT days 0.419*
Median (range) 44 (40–54) 43 (40–54) 44 (40–55)
IC regimen 0.838†
PF - 28 (57.1 %) 29 (59.2 %)
TP - 21 (42.9 %) 20 (40.8 %)
IC cycles 0.170†
Two cycles - 33 (67.3 %) 39 (79.6 %)
Three cycles - 16 (32.7 %) 10 (20.4 %)
CCRT cycles 0.233†
Two cycles 40 (81.6 %) - 45 (91.8 %)
Three cycles 9 (18.4 %) - 4 (8.2 %)
Abbreviations: IC induction chemotherapy, RT radiotherapy; CCRT concurrent chemoradiotherapy
*P-values were calculated using ANOVA
†P-values were calculated using the Chi-square test (or Fisher’s exact test, if the expected number was less than five in at least 25 % of the cells)
Table 1 Characteristics of the 147 propensity-matched patients
Characteristic CCRT group (n = 49) IC plus RT group (n = 49) IC plus CCRT group (n = 49) P value*
Sex 0.672
Male 32 (65.3 %) 31 (63.3 %) 35 (71.4 %)
Female 17 (34.7 %) 18 (36.7 %) 14 (28.6 %)
Age (years) 0.696
≤45 19 (38.8 %) 20 (40.8 %) 23 (46.9 %)
>45 30 (61.2 %) 29 (59.2 %) 26 (53.1 %)
Histological type -
WHO type I 0 (0 %) 0 (0 %) 0 (0 %)
WHO type II/III 49 (100 %) 49 (100 %) 49 (100 %)
T-category 1.000
T1 1 (2 %) 0 (0 %) 0 (0 %)
T2 1 (2 %) 2 (4.1 %) 2 (4.1 %)
T3 32 (65.3 %) 33 (67.3 %) 32 (65.3 %)
T4 15 (30.6 %) 14 (28.6 %) 15 (30.6 %)
N-category 0.956
N0 4 (8.2 %) 4 (8.2 %) 4 (8.2 %)
N1 29 (59.2 %) 27 (55.1 %) 28 (57.1 %)
N2 10 (20.4 %) 13 (26.5 %) 9 (18.4 %)
N3 6 (12.2 %) 5 (10.2 %) 8 (16.3 %)
Stage-group 0.891
III 31 (63.3 %) 31 (63.3 %) 29 (59.2 %)
IVA-B 18 (36.7 %) 18 (36.7 %) 20 (40.8 %)
Abbreviations: IC induction chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy
*P-values were calculated using the Chi-square test (or Fisher’s exact test, if the expected number was less than five in at least 25 % of the cells)
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grade 3 – 4 hematological toxicity was leucopenia in four
patients (8.2 %) in the CCRT group, 10 patients (20.4 %)
in the IC plus RT group, and 11 patients (22.4 %) in the IC
plus CCRT group (P = 0.126). The most commonly re-
corded non-hematological adverse event was grade 3 – 4
mucositis in 11 patients (22.4 %) in the CCRT group,
seven patients (14.3 %) in the IC plus RT group, and 12
patients (24.5 %) in the IC plus CCRT group (P = 0.415).
Discussion
To our knowledge, this is the first study to compare the
survival outcomes and toxicities of CCRT, IC plus RT,
and IC plus CCRT in patients with locoregionally ad-
vanced NPC treated using IMRT. All patients received
at least two cycles of IC based on PF or TP regimens,
and/or at least two cycles of concurrent chemotherapy
based on cisplatin every three weeks. Moreover, a pro-
pensity score matching method was used to adjust for
differences in the baseline characteristics of the patients
and reduce selection bias, in order to enable an accurate
comparison of the efficacies of these chemotherapy se-
quences. However, no statistically significant differences
in DFS, OS, DMFS or LRRFS were observed between the
three treatment groups.
Table 3 Comparison of the survival rates for each treatment group
Comparison IC plus RT vs. CCRT IC plus CCRT vs. CCRT IC plus CCRT vs. IC plus RT
(n = 98) (n = 98) (n = 98)
Three-year DFS 86.3 % vs. 82.1 % 87.8 % vs. 82.1 % 87.8 % vs. 86.3 %
P value* 0.592 0.533 0.924
Three-year OS 91 % vs. 92.8 % 95.8 % vs. 92.8 % 95.8 % vs. 91 %
P value* 0.987 0.318 0.390
Three-year DMFS 91.6 % vs. 87 % 93.8 % vs. 87 % 93.8 % vs. 91.6 %
P value* 0.526 0.290 0.676
Three-year LRRFS 94.4 % vs. 90.4 % 93.9 % vs. 90.4 % 93.9 % vs. 94.4 %
P value* 0.425 0.646 0.709
Abbreviations: IC induction chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy, DFS disease–free survival, OS overall survival, DMFS distant
metastasis–free survival, LRRFS, Locoregional relapse–free survival
*P-values were calculated using the unadjusted log–rank test
Fig. 1 Kaplan–Meier survival curves. Disease–free survival (a), overall survival (b), distant metastasis–free survival (c) and locoregional relapse–free
survival (d) for the CCRT group, IC plus RT group and IC plus CCRT group. P-values were calculated using the unadjusted log–rank test. IC,
induction chemotherapy; RT, radiotherapy; CCRT, concurrent chemoradiotherapy
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Both induction and concurrent chemotherapy are ef-
fective treatment strategies for NPC [10–12, 21]; how-
ever, the optimal chemotherapy sequence that may
further improve the survival rate in NPC remains to be
identified. Only one phase 3 trial, by Xu et al., has com-
pared IC plus RT and adjuvant chemotherapy versus
CCRT plus adjuvant chemotherapy in locoregionally ad-
vanced NPC [29], in which 2DCRT was adopted as the
RT technique and a PF regimen was used in the induc-
tion, concurrent and adjuvant phases. Both groups
achieved similar outcomes. However, the combination of
adjuvant chemotherapy may have narrowed the survival
differences between the two treatment groups [29]. In
two retrospective studies comparing IC plus RT with
CCRT, no significant differences in survival were re-
ported. However, the locoregional control rate seemed
to be slightly better in the CCRT group than the IC plus
RT group [30, 31]. However, none of these studies were
entirely based on patients treated with IMRT.
All patients analyzed in this study received IMRT. The
IC plus RT group had similar 3-year DFS (86.3 % vs.
82.1 %, P = 0.592), OS (91 % vs. 92.8 %, P = 0.987),
DMFS (91.6 % vs. 87 %, p = 0.526), and LRRFS (94.4 %
vs. 90.4 %, P = 0.425) rates compared to the CCRT
group. These results suggest that IC plus RT is equiva-
lent to CCRT in patients treated using IMRT, and that
the improved locoregional control provided by IMRT
may minimize the survival benefit of concurrent chemo-
therapy. However, it should be noted that higher-
intensity regimens (PF or TP vs. cisplatin) were used
and there were more patients who received three cycles
of chemotherapy (32.7 % vs. 18.4 %) in the induction
Table 4 Summary of multivariate analyses of prognostic factors in the 147 propensity-matched patients
Endpoint Factor HR 95 % CI P value*
Disease failure Age >45 yrs vs. ≤45 yrs 1.30 0.48-3.53 0.603
Sex female vs. male 0.59 0.21-1.65 0.310
AJCC T-category T4 vs. T1-3 2.47 1.01-6.07 0.048
AJCC N-category N2-3 vs. N0-1 3.72 1.49-9.25 0.005
RT dose >68 Gy vs. 68 Gy 0.51 0.21-1.23 0.133
Treatment group IC plus RT vs. CCRT 0.83 0.29-2.42 0.734
Treatment group IC plus CCRT vs. CCRT 0.79 0.26-2.37 0.669
Death Age >45 yrs vs. ≤45 yrs 2.69 0.57-12.76 0.212
Sex female vs. male 1.46 0.40-5.35 0.572
AJCC T-category T4 vs. T1-3 1.58 0.42-6.00 0.499
AJCC N-category N2-3 vs. N0-1 2.97 0.84-10.54 0.092
RT dose >68 Gy vs. 68 Gy 0.29 0.07-1.12 0.071
Treatment group IC plus RT vs. CCRT 1.19 0.29-4.93 0.813
Treatment group IC plus CCRT vs. CCRT 0.64 0.11-3.85 0.622
Distant failure Age >45 yrs vs. ≤45 yrs 1.97 0.54-7.25 0.306
Sex female vs. male 0.59 0.15-2.26 0.437
AJCC T-category T4 vs. T1-3 2.97 0.98-9.00 0.054
AJCC N-category N2-3 vs. N0-1 8.38 2.26-31.06 0.001
RT dose >68 Gy vs. 68 Gy 0.53 0.18-1.57 0.248
Treatment group IC plus RT vs. CCRT 0.67 0.19-2.41 0.541
Treatment group IC plus CCRT vs. CCRT 0.48 0.11-2.00 0.310
Locoregional Age >45 yrs vs. ≤45 yrs 0.62 0.15-2.52 0.506
failure Sex female vs. male 0.59 0.12-2.86 0.514
AJCC T-category T4 vs. T1-3 2.88 0.77-10.72 0.115
AJCC N-category N2-3 vs. N0-1 1.31 0.32-5.41 0.705
RT dose >68 Gy vs. 68 Gy 0.54 0.14-1.99 0.351
Treatment group IC plus RT vs. CCRT 0.51 0.09-2.82 0.443
Treatment group IC plus CCRT vs. CCRT 0.77 0.16-3.65 0.738
Abbreviations: HR hazard ratio, CI confidence interval, IC induction chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy
*P-values were calculated using the adjusted Cox proportional-hazards model
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phase than in the concurrent phase; thus, the efficacy of
IC versus concurrent chemotherapy in NPC patients
treated with IMRT requires further evaluation.
IC plus CCRT has been proposed as a promising treat-
ment strategy that may provide a survival benefit in locor-
egionally advanced NPC. The assumption is that
increased cycles of chemotherapy could further reduce
disease recurrence in high-risk patients. Several random-
ized trials have compared IC plus CCRT vs. CCRT
[18–20] or IC plus CCRT vs. IC plus RT [32]. How-
ever, the efficacy of induction-concurrent strategies
remains controversial. In a phase 2 study by Hui et
al., addition of a TP-based IC regimen to CCRT sig-
nificantly increased 3-year OS (94.1 % vs. 67.7 %, P =
0.012), and potentially improved progression–free sur-
vival and reduced distant metastasis compared to
CCRT alone [18]. However, in two other randomized
trials, IC using CEP (cisplatin, epirubicin, paclitaxel)
[19] or GCP (gemcitabine, carboplatin, paclitaxel) [20]
failed to show a survival benefit when added to
CCRT. Huang et al. conducted a phase 3 randomized
trial comparing IC plus CCRT with IC plus RT. No
significant differences in survival were observed be-
tween the two treatment groups, and the authors
concluded that concurrent carboplatin was the main
reason for the negative results [32].
In this study, the IC plus CCRT group demonstrated
no significant improvement in OS, DFS, DMFS or
LRRFS over the CCRT group or IC plus RT group. Sev-
eral factors could explain these negative results. Firstly,
each treatment group had only 49 matched patients.
The relatively small sample size may have meant the
study was underpowered to detect differences in sur-
vival, especially with regards to NPC patients treated
with IMRT. Secondly, only a few patients received three
cycles of IC and concurrent 80–100 mg/m2 cisplatin in
the IC plus CCRT group, which may have reduced the
effectiveness of IC and CCRT [20]. Thirdly, truly high-
risk patients who may benefit from more cycles of
chemotherapy may be yet to be identified. Fourthly, it is
possible that the use of other more effective chemother-
apy regimens could provide additional survival benefit,
such as induction TPF (docetaxel, cisplatin and fluoro-
uracil) [33, 34] and PX (cisplatin and capecitabine) [35].
Therefore, the efficacy of IC plus CCRT requires further
investigation.
The toxicity profiles of all three treatment groups were
similar. There was a slightly lower incidence of grade 3–4
hematological toxicities in the CCRT group, and a lower
incidence of grade 3–4 mucositis in the IC plus RT group;
however, these differences were not significant. Notably,
the incidence of grade 3–4 acute toxicities was lower than
the rates reported in randomized trials [3–9, 18]; the main
reasons for this observation may be the retrospective na-
ture of this study, primary prophylaxis with granulocyte
colony-stimulating factor, or inadequate monitoring of the
adverse events in outpatients.
In this study, CCRT, IC plus RT, and IC plus CCRT
led to similar survival outcomes and acute toxicities in
patients with locoregionally advanced NPC treated using
Table 5 Adverse events
Variable CCRT group (n = 49) IC plus RT group (n = 49) IC plus CCRT group (n = 49) P value*
Total Grade 3–4 acute adverse events 16 (32.7 %) 19 (38.8 %) 20 (40.8 %) 0.685
Hematologic
Leukopenia 4 (8.2 %) 10 (20.4 %) 11 (22.4 %) 0.126
Neutropenia 3 (6.1 %) 9 (18.4 %) 9 (18.4 %) 0.135
Anemia 0 (0 %) 1 (2 %) 1 (2 %) 1.000
Thrombocytopenia 2 (4.1 %) 2 (4.1 %) 2 (4.1 %) 1.000
Non–hematologic
Dermatitis 1 (2 %) 2 (4.1 %) 2 (4.1 %) 1.000
Mucositis 11 (22.4 %) 7 (14.3 %) 12 (24.5 %) 0.415
Dysphagia 1 (2 %) 0 (0 %) 1 (2 %) 1.000
Nausea/vomiting 2 (4.1 %) 2 (4.1 %) 3 (6.1 %) 1.000
Dry mouth 0 (0 %) 0 (0 %) 0 (0 %) -
Ototoxicity 0 (0 %) 0 (0 %) 0 (0 %) -
Hepatoxicity 0 (0 %) 3 (6.1 %) 1 (2 %) 0.324
Nephrotoxicity 0 (0 %) 0 (0 %) 0 (0 %) -
Neurotoxicity 0 (0 %) 0 (0 %) 0 (0 %) -
Abbreviations: IC induction chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy
*P-values were calculated using the Chi-square test (or Fisher’s exact test, if the expected number was less than five in at least 25 % of the cells)
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IMRT. However, it should be noted that this is a
retrospective study with a relatively small sample size
(n = 147) and a short follow-up (median, 38.5 months).
Thus, the findings of this study require validation in
phase 3 trials; the question of what chemotherapy
should be given with IMRT for locoregionally ad-
vanced NPC remains unanswered.
Conclusions
In conclusion, the results of this study suggest that
CCRT, IC plus RT, and IC plus CCRT are similarly effi-
cacious treatment strategies for patients with locoregion-
ally advanced NPC treated using IMRT. The results of
this study need to be confirmed by long-term, large-
scale prospective trials.
Abbreviations
NPC: Nasopharyngeal carcinoma; IMRT: Intensity-modulated radiotherapy;
2DCRT: Two-dimensional conventional radiotherapy; RT: Radiotherapy;
CCRT: Concurrent chemoradiotherapy; IC: Induction chemotherapy;
OS: Overall survival; DFS: Disease–free survival; DMFS: Distant metastasis–free
survival; LRRFS: Locoregional relapse–free survival; SPECT: Single photon
emission computed tomography; PTV: Planning target volume; GTV: Gross
tumor volume; CTV: Clinical target volume; HR: Hazard ratio; CI: Confidence
interval.
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